NorthWest Biotherapeutics Inc (NWBO)

[JerryCampbell]

New prospectus on the SEC website.

https://www.sec.gov/Archives/edgar/data/1072379/000110465920114289/tm2033071-1_424b5.htm

On October 12, 2020, the Company entered into financings totaling $11,900,570 pursuant to this prospectus supplement (the “Offering”). The financings were comprised of:

· $9,975,570 from an offering at $0.816 per share (based upon the average 10 day closing price ending on October 12, 2020) of newly registered common stock of approximately 12.2 million shares with 30% warrants with an exercise price of $2.00 per share and an exercise period of 12 months (following a 3-month suspension after issuance), and

· $1,925,00 million from a convertible note which is convertible at $0.85 per share (the “Note”). The Note carries no warrants unless it is converted. If, and only to the extent, the Note is converted it will carry 30% warrants with an exercise price of $2.00 per share and an exercise period of 12 months (following a 3-month suspension after issuance).

All of the new warrants issued in the Offering are suspended until January 15, 2021.

In addition, as part of these agreements, certain investors who have existing outstanding warrants that have not yet been suspended are now suspending approximately 3.54 million additional existing warrant exercise shares until January 15, 2021. In consideration for the suspension of the 3.54 million existing warrant shares as part of the Offering, the Company issued approximately 261,000 warrants with an exercise price of $2.00 per share and an exercise period of 12 months (following a 3-month suspension after issuance). These suspension consideration warrants are also suspended until the same January date.